Bioresorbable, Injectable In Situ-Formed Electroactive mRNA-Delivering Device for Precision Gene Therapy after Myocardial Infarction
- 1Lund University
Abstract
Myocardial infarction (MI) causes irreversible cardiomyocyte loss and triggers inflammatory and fibrotic remodeling that promote the progression to heart failure. Although regenerative gene therapy offers a promising route to cardiac repair, clinical translation has been limited because of the lack of targeted, minimally invasive, and clinically scalable delivery strategies. Here we report an injectable, bioresorbable in situ-formed electroactive device that enables local mRNA delivery through the pericardial space, a clinically established route of access. Following administration, the formulation self-assembles into a transient conductive mRNA-carrying drape electrode over the injured heart, enabling in vivo electrotransfection, and is then bioresorbed, eliminating the need for retrieval. In animal models, the formulation was well tolerated, did not disrupt cardiac contractile activity, and enabled targeted mRNA transfer. In a mouse model of MI, localized delivery of vascular endothelial growth factor (VEGF-A) mRNA attenuated adverse remodeling, improved cardiac function (e.g., stroke volume and ejection fraction were fully recovered), and established a minimally invasive strategy for localized regenerative gene delivery to the injured heart.
Related
- A NET-associated immunothrombotic phenotype is associated with coronary no-reflow and myocardial injury after primary PCI in ST-segment elevation myocardial infarction: a real-world translational cohort
- From marrow memory to adverse ventricular remodeling: trained immunity after myocardial infarction
- Poor survival after myocardial infarction in immune deficient NXG B2m mice is alleviated by transplantation of induced pluripotent stem cell derived cardiomyocytes (iPSC-CM) formulated as spheres, but not single cells
- Re. The influence of personality on the risk of myocardial infarction in UK Biobank cohort
- The CXCL12γ/ACKR3 Axis Is a Critical Determinant of Myocardial Angiogenesis and Functional Recovery After Infarction
BibTeX
@misc{aydemir2026bioresorbable,
title = {{Bioresorbable, Injectable In Situ-Formed Electroactive mRNA-Delivering Device for Precision Gene Therapy after Myocardial Infarction}},
author = {U. Aydemir and S. Sahoglu Goktas and U. Dasmahapatra and A. S. Yadav and K. Hellman and S. Sumit and F. Ek and A. Arner and A. Meissner and m. hjort and R. Olsson},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.29.758467},
url = {https://www.biorxiv.org/content/10.64898/2026.10.29.758467v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Bioresorbable, Injectable In Situ-Formed Electroactive mRNA-Delivering Device for Precision Gene Therapy after Myocardial Infarction
AU - U. Aydemir
AU - S. Sahoglu Goktas
AU - U. Dasmahapatra
AU - A. S. Yadav
AU - K. Hellman
AU - S. Sumit
AU - F. Ek
AU - A. Arner
AU - A. Meissner
AU - m. hjort
AU - R. Olsson
PY - 2026
DA - 2026/10/29
PB - bioRxiv
DO - 10.64898/2026.10.29.758467
UR - https://www.biorxiv.org/content/10.64898/2026.10.29.758467v1
AB - Myocardial infarction (MI) causes irreversible cardiomyocyte loss and triggers inflammatory and fibrotic remodeling that promote the progression to heart failure. Although regenerative gene therapy offers a promising route to cardiac repair, clinical translation has been limited because of the lack of targeted, minimally invasive, and clinically scalable delivery strategies. Here we report an injectable, bioresorbable in situ-formed electroactive device that enables local mRNA delivery through the pericardial space, a clinically established route of access. Following administration, the formulation self-assembles into a transient conductive mRNA-carrying drape electrode over the injured heart, enabling in vivo electrotransfection, and is then bioresorbed, eliminating the need for retrieval. In animal models, the formulation was well tolerated, did not disrupt cardiac contractile activity, and enabled targeted mRNA transfer. In a mouse model of MI, localized delivery of vascular endothelial growth factor (VEGF-A) mRNA attenuated adverse remodeling, improved cardiac function (e.g., stroke volume and ejection fraction were fully recovered), and established a minimally invasive strategy for localized regenerative gene delivery to the injured heart.
ER -